SCHEMBL3553979

SCHEMBL3553979

O=C(O)c1ccc(OCCOc2ccccc2NS(=O)(=O)c2cccc(F)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.48
SLC16A3 O15427 2/20 0.48
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
PTPN1 P18031 1/20 0.47
NR4A2 P43354 1/20 0.47
PKM P14618 1/20 0.47
CACNA1H O95180 1/20 0.47
CACNA1B Q00975 1/20 0.47
ATM Q13315 1/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
TSHR P16473 1/20 0.46
PTK2B Q14289 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
MCL1 Q07820 1/20 0.45
BCL2A1 Q16548 1/20 0.45
PTGDR2 Q9Y5Y4 1/20 0.45
WDR5 P61964 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3561665 0.89 CACNA1H (0.58) SLC16A3KMT2AMEN1PTPN1PKM
SCHEMBL3554494 0.89 PKM (0.56) SLC16A3KMT2AMEN1PTPN1PKM
SCHEMBL3562684 0.88 SLC16A3 (0.50) SLC16A3KMT2AMEN1PKMCACNA1H
SCHEMBL3558121 0.87 MEN1 (0.59) PGRSLC16A3KMT2AMEN1NR4A2
SCHEMBL3554984 0.87 PKM (0.56) SLC16A3PTPN1PKMCACNA1HCACNA1B
SCHEMBL3560287 0.87 SLC16A3 (0.64) PGRSLC16A3KMT2AMEN1PKM
SCHEMBL3556446 0.86 PGR (0.62) PGRKMT2AMEN1NR4A2PKM
SCHEMBL3552423 0.85 PIK3CA (0.50) SLC16A3PTPN1NR4A2PKMCACNA1H
SCHEMBL3556152 0.85 SLC16A3 (0.61) SLC16A3KMT2AMEN1PTPN1PKM
SCHEMBL3553928 0.84 PKM (0.50) SLC16A3KMT2AMEN1PKMCACNA1H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 PGR 1338/4885SLC16A3 425/4885KMT2A 4045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.